PMID- 36143987
OWN - NLM
STAT- MEDLINE
DCOM- 20220926
LR  - 20230308
IS  - 1648-9144 (Electronic)
IS  - 1010-660X (Print)
IS  - 1010-660X (Linking)
VI  - 58
IP  - 9
DP  - 2022 Sep 19
TI  - Therapeutic Efficacy of Weissella cibaria CMU and CMS1 on Allergic Inflammation 
      Exacerbated by Diesel Exhaust Particulate Matter in a Murine Asthma Model.
LID - 10.3390/medicina58091310 [doi]
LID - 1310
AB  - Background and Objectives: Diesel exhaust particulate matter (DEPM) is an air 
      pollutant that is associated with asthma. In this study, the therapeutic efficacy 
      of Weissella cibaria strains CMU (Chonnam Medical University) and CMS (Chonnam 
      Medical School) 1, together with the drug Synatura, an anti-tussive expectorant, 
      was investigated in a murine asthma model exacerbated by DEPM. Materials and 
      Methods: BALB/c mice were sensitized with ovalbumin (OVA) before intranasal 
      challenge with OVA and DEPM. W. cibaria CMU, CMS1, and Synatura were administered 
      orally for 21 days. Results: Neither Synatura nor W. cibaria strains affected 
      spleen, liver, or lung weights. W. cibaria strains CMU and CMS1 significantly 
      reduced the levels of interleukin (IL)-4, OVA-specific immunoglobulin E (IgE), 
      and total lung collagen in bronchoalveolar lavage fluid (BALF), similar to those 
      with Synatura, regardless of the oral dose concentration (p < 0.05). In addition, 
      the W. cibaria CMU strain significantly alleviated IL-1beta, IL-6, IL-12, monocyte 
      chemotactic protein-1, and tumor necrosis factor-alpha in BALF, whereas the CMS1 
      strain significantly alleviated IL-10 and IL-12 in BALF (p < 0.05); however, 
      Synatura did not show any statistical efficacy against them (p > 0.05). All 
      concentrations of W. cibaria CMU and low concentrations of W. cibaria CMS1 
      significantly reduced lung bronchiolar changes and inflammatory cell 
      infiltration. Conclusions: In conclusion, W. cibaria CMU in asthmatic mice showed 
      better efficacy than W. cibaria CMS1 in improving asthma exacerbated by DEPM 
      exposure, as well as better results than pharmaceuticals.
FAU - Do, Kyung-Hyo
AU  - Do KH
AD  - Laboratory of Veterinary Bacteriology and Infectious Diseases, College of 
      Veterinary Medicine, Chungbuk National University, Cheongju 28644, Korea.
FAU - Seo, Kwangwon
AU  - Seo K
AD  - College of Veterinary Medicine, Chungbuk National University, Cheongju 28644, 
      Korea.
FAU - Kim, Sanggu
AU  - Kim S
AD  - Laboratory of Veterinary Pathology and Platelet Signaling, College of Veterinary 
      Medicine, Chungbuk National University, Cheongju 28644, Korea.
FAU - Kim, Soochong
AU  - Kim S
AD  - Laboratory of Veterinary Pathology and Platelet Signaling, College of Veterinary 
      Medicine, Chungbuk National University, Cheongju 28644, Korea.
FAU - Park, Geun-Yeong
AU  - Park GY
AUID- ORCID: 0000-0001-9492-6768
AD  - R&D Center, OraPharm, Inc., Seoul 04782, Korea.
FAU - Kang, Mi-Sun
AU  - Kang MS
AUID- ORCID: 0000-0001-8078-4666
AD  - R&D Center, OraPharm, Inc., Seoul 04782, Korea.
FAU - Lee, Wan-Kyu
AU  - Lee WK
AD  - Laboratory of Veterinary Bacteriology and Infectious Diseases, College of 
      Veterinary Medicine, Chungbuk National University, Cheongju 28644, Korea.
LA  - eng
GR  - 120050-2/Korea Institute of Planning and Evaluation for Technology in Food, 
      Agriculture, Forestry and Fisheries/
GR  - 2020R1F1A1069551/Basic Science Research Program of the National Research 
      Foundation of Korea/
PT  - Journal Article
DEP - 20220919
PL  - Switzerland
TA  - Medicina (Kaunas)
JT  - Medicina (Kaunas, Lithuania)
JID - 9425208
RN  - 0 (Air Pollutants)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Cytokines)
RN  - 0 (Expectorants)
RN  - 0 (Interleukin-6)
RN  - 0 (Particulate Matter)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 0 (Vehicle Emissions)
RN  - 130068-27-8 (Interleukin-10)
RN  - 187348-17-0 (Interleukin-12)
RN  - 37341-29-0 (Immunoglobulin E)
RN  - 9006-59-1 (Ovalbumin)
RN  - Weissella cibaria
SB  - IM
MH  - *Air Pollutants
MH  - Animals
MH  - *Asthma/chemically induced/drug therapy
MH  - Chemokine CCL2/therapeutic use
MH  - Cytokines
MH  - Disease Models, Animal
MH  - Expectorants/therapeutic use
MH  - Humans
MH  - Immunoglobulin E
MH  - Inflammation
MH  - Interleukin-10
MH  - Interleukin-12
MH  - Interleukin-6
MH  - Lung
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Ovalbumin
MH  - Particulate Matter
MH  - Tumor Necrosis Factor-alpha
MH  - Vehicle Emissions/toxicity
MH  - Weissella
PMC - PMC9500616
OTO - NOTNLM
OT  - Weissella cibaria CMS1
OT  - Weissella cibaria CMU
OT  - asthma
OT  - bronchial hyper-responsiveness
OT  - inflammation
COIS- The authors declare no conflict of interest.
EDAT- 2022/09/24 06:00
MHDA- 2022/09/28 06:00
PMCR- 2022/09/19
CRDT- 2022/09/23 01:33
PHST- 2022/07/26 00:00 [received]
PHST- 2022/09/12 00:00 [revised]
PHST- 2022/09/13 00:00 [accepted]
PHST- 2022/09/23 01:33 [entrez]
PHST- 2022/09/24 06:00 [pubmed]
PHST- 2022/09/28 06:00 [medline]
PHST- 2022/09/19 00:00 [pmc-release]
AID - medicina58091310 [pii]
AID - medicina-58-01310 [pii]
AID - 10.3390/medicina58091310 [doi]
PST - epublish
SO  - Medicina (Kaunas). 2022 Sep 19;58(9):1310. doi: 10.3390/medicina58091310.